<?xml version="1.0" encoding="UTF-8"?>
<Label drug="ddavp1" track="TAC2017_ADR">
  <Text>
    <Section name="adverse reactions" id="S1">    ADVERSE REACTIONS

  Infrequently, large doses of the intranasal formulations of DDAVP and DDAVP Injection have produced transient headache, nausea, flushing and mild abdominal cramps. These symptoms have disappeared with reduction in dosage.



   Central Diabetes Insipidus

  In long-term clinical studies in which patients with diabetes insipidus were followed for periods up to 44 months of  DDAVP Tablet  therapy, transient increases in AST (SGOT) no higher than 1.5 times the upper limit of normal were occasionally observed. Elevated AST (SGOT) returned to the normal range despite continued use of  DDAVP Tablets  .



   Primary Nocturnal Enuresis

  The only adverse event occurring in &gt;=3% of patients in controlled clinical trials with  DDAVP Tablets  that was probably, possibly, or remotely related to study drug was headache (4% DDAVP, 3% placebo).



   Other

  The following adverse events have been reported; however their relationship to DDAVP has not been established: abnormal thinking, diarrhea, and edema-weight gain. See    WARNINGS    for the possibility of water intoxication and hyponatremia.



   Post Marketing:  There have been rare reports of hyponatremic convulsions associated with concomitant use with the following medications: oxybutinin and imipramine.
</Section>
  </Text>
  <Mentions />
  <Relations />
  <Reactions />
</Label>
